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isolated perfused kidney
JOCELYN R. SAUNDERS, ATOUSA AMINIAN, JENNIFER L. MCRAE, KATRINA A. O'FARRELL,
WILLIAM R. ADAM, and BRENDAN F. MURPHY
Department of Nephrology, St. Vincent's Hospital and Department of Medicine, University of Melbourne, and Renal Unit, Heidelberg
Repatriation Hospital, Melbourne, Victoria, Australia
Clusterin depletion enhances immune glomerular injury in the isolated
perfused kidney. Clusterin is a normal plasma protein, shown to be an
inhibitor of reactive complement hemolysis and a component of the
fluid phase SC5b-9 terminal complement complexes. It is a component
of glomerular immune deposits in human and experimental glomerulo-
nephritis. Using the complement-dependent isolated perfused rat kid-
ney model of autologous phase passive Heymann nephritis, we have
studied the effect of clusterin depletion of perfused plasma on the
development of glomerular injury. Kidneys with planted glomerular
sheep anti-rat Fx1A antibody were perfused with human plasma either
depleted of clustenn to  30%, or control plasma depleted of plasma
fibronectin. Glomerular injury was then initiated by the addition of
guinea pig anti-sheep immunoglobulins to the perfusate. Kidneys per-
fused with clusterin depleted plasma developed significantly greater
proteinuria at all time points when compared to control kidneys.
Glomerular antibody binding and C3 deposition were similar in the two
groups, but terminal complement components were deposited in larger
amounts in the clusterin depleted group. These data support a possible
role for clusterin in vivo in the protection of complement-induced
glomerular injury.
Human clusterin (SP-40,40) is a normal plasma protein which
was first identified by the production of murine monoclonal
antibodies (mAb) raised against the pathological glomerular
basement membrane of a patient with membranous glomerulo-
nephritis [1]. Clusterin was previously identified in the repro-
ductive tracts of the rat and ram as a major secretory product of
rat Sertoli cells in culture and a promoter of cell aggregation in
ram rete testis fluid, hence the name clusterin [2].
Subsequently numerous groups have cloned homologues of
the same protein in a variety of mammalian species and in a
surprising variety of biological systems. The various names
given to this protein are listed in Table 1.
In the kidney, clusterin has been found in two principal
situations: in association with SC5b-9 terminal complement
complexes and acutely in areas of renal injury [18, 19]. Clus-
term has been detected both in glomerular immune deposits and
also in extraglomerular sites of SC5b-9 deposition in the ab-
sence of immunoglobulin and early complement components.
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In one study of human renal biopsies glomerular clusterin
deposition corresponded exactly to that of C5b-9 components
and vitronectin [18]. Another recent biopsy study suggested
that there was also an association between glomerular IgG and
clusterin deposition [20]. In the experimental model of passive
Heymann nephritis in the rat, clusterin deposition was seen in
the glomeruli in association with C5b-9 and proteinuria. In this
study decomplementation, which prevented C5b-9 deposition
and proteinuria, was also associated with an absence of glomer-
ular clusterin [21].
In vitro clusterin has been demonstrated to be an inhibitor of
C5b-6 reactive hemolysis [22, 23]. It has been proposed that,
analogous to vitronectin, clustenn binds to the unstable C5b-7
complex inhibiting the insertion of the complex into phospho-
lipid cell membranes. Clusterin is then incorporated, together
with vitronectin, into the soluble non-lytic SC5b-9 complement
complex [22, 23].
It is possible, therefore, that clusterin in vivo is acting as a
regulator of C5b-9 induced cell injury, and its presence in
glomerular immune deposits represents a host limitation of
complement injury by preventing C5b-9 insertion into cell
membranes in the glomerulus.
We sought to test this hypothesis in a functional model of
experimental glomerulonephritis where depletion of plasma
clusterin would be achievable. The previously described [24],
CSb-9 dependent, isolated perfused kidney model of autologous
phase passive Heymann nephrttis using perfused human plasma
as a source of complement seemed well suited to this purpose.
In this model, we have studied the effect on immune glomerular
injury of depletion of clusterin from the perfused human
plasma.
Methods
Kidney perfusions
The technique of kidney perfusion was as described previ-
ously by Cybulsky et al [24] with the exception that depleted
and diluted human plasma was used to completely replace the
standard BSA perfusate after establishment of perfusion. In the
previous study [24] an equal volume of human plasma was
added into the BSA perfusate after commencement of perfu-
sion.
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Table 1. Synonyms of clusterin
Name Reference
Clusterin [3]
SGP-2 (suiphated glycoprotein 2) [41
[51
GP-II1 (glycoprotein III) [6, 7]
TRPM-2 (testosterone-repressed prostrate message) [8, 9]
Gp 80 (glycoprotein 80 kD) [10]
SP-40,40 (serum protein having two 40 kD subunits) [1]
CLI (cytolysis inhibitor) [23]
TM (message induced by v-src oncogene) [11]
Apo J (apoliprotein J) [12, 13]
pADHC-9, pTB-16, K-661 (gene clones) [14—171
BSA perfusate
The following preparation of the BSA perfusate was based on
that used by Cybulsky [241.
A 20% BSA (Sigma) solution which had been extensively
dialyzed against Krebs-Henseleit buffer (KHB) (5 times 5 vol
for a total of 72 hr) was diluted in KHB to produce a final
concentration of BSA of 80 mg/mi. Amino acids, glucose and
calcium chloride were added to achieve a final composition in
the BSA perfusate of (in mmol/liter); glucose 5.0; calcium. 3.0;
sodium 140; magnesium 1.2; chloride 119; inorganic phosphate
1.2; SO4 1,2; HCO3 25, with the amino acids lysine 2.0; tyrosine
0.48; glutamine 4.2; glutamate 1.1; aspartate 0.4; asparagine
0.4; serine 2.0; cysteine 1.5; glycine 4.6; histidine 0.6; threonine
0.7; tryptophan 0.18; leucine 1.12; phenylalanine 0.72; isole-
ucine 1.0; methionine 0.6; valine 1.0; arginine 2.6; proline 1.2;
and alanine 4.6.
Verapamil (Knoll AG. Germany) was also added to a final
concentration of i0 M to prevent renal vasoconstriction [24].
Prior to use, perfusate was filtered through 8 jsm and 0.45 m
filters (Millipore).
Preparation of human plasma
Two hundred fifty milliliters of fresh normal human plasma in
acid citrate dextrose were collected by centrifugation of 500 ml
of fresh blood (1000 g, 10 mm) taken from a normal volunteer
on the day prior to the perfusion. Sodium ethylenediamine-
tetraacetic acid (EDTA) was made 10 m in the plasma and the
plasma divided into two portions. Half of the plasma was
depleted of clusterin and the other half depleted of fibronectin
by affinity depletion chromatography as described below.
Depletion of plasma clusterin. Clusterin depletion was per-
formed using a 10 ml column of cyanogen bromide activated
Sepharose 4B (Pharmacia, Sweden) to which 80 mg of the G7
anti-clusterin monoclonal antibody [1] had been coupled ac-
cording to the manufacturer's instructions. The column was
equilibrated in 0.1 M phosphate buffered saline containing
10 mM EDTA (PBS-EDTA) and plasma passaged though in
10 ml aliquots. Each aliquot was washed through the column
with PBS-EDTA and collected. The column was then eluted
with 5 ml glycine HC1 (pH 2.8) and re-equilibrated with PBS-
EDTA before passage of another 10 ml of plasma. All proce-
dures were carried out at 4°C. After all plasma had been
passaged through the column, it was pooled and dialyzed
overnight against 10 volumes of Krebs-Henseleit buffer (KHB)
(without calcium) prior to use in the perfusion the following
day. Dilution of the plasma during the affinity depletion resulted
in a reduction in total plasma protein concentration to 55 to 60%
of the initial level. Samples of the depleted plasma were stored
at —20°C for later quantitation of the degree of clusterin
depletion.
Control plasma depletion of plasma fibronectin. To control
for complement inactivation by passage through affinity col-
umns the control plasma was treated exactly as the clusterin
depleted plasma with the exception that the affinity column was
coupled to 80 mg of the monoclonal antibody against plasma
fibronectin PHM 13 [25].
Quantitation of clusterin and fibronectin depletion. Follow-
ing affinity depletion, samples of each plasma before and after
affinity depletion were assayed by ELISA as previously de-
scribed [11 to determine the proportion of plasma clustenn or
fibronectin removed during each chromatographic procedure.
Modification of plasma prior to perfusion. After dialysis,
clusterin depleted and control plasma were made up to a final
albumin concentration of 60 mg/ml by the addition of a 20%
BSA (Sigma) in KHB. In addition heparin (6 U/ml) (Common-
wealth Serum Laboratories, Melbourne, Australia), verapamil
l0 M (Knoll AG., Germany), and additional amino acids [(all
in mmollliter); lysine 1.0; tyrosine 0.24; glutamine 2.1; gluta-
mate 0.5; aspartate 0.2; asparagine 0.2; serine 1.0; cysteine
0.75; glycine 2.3; histidine 0.3; threonine 0.35; tryptophan 0.09;
leucine 0.6; phenylalanine 0.36; isoleucine 0.5; methionine 0.3;
valine 0.5; arginine 1.3; proline 0.6; and alanine 2.3] were added
together with glucose 5 mmollliter and calcium 2.5 mmollliter.
The plasma was filtered through 8 m and 0.45 m filters
(Millipore) immediately before use.
Perfusion set up and animals
The perfusion circuit was as described by Ellis and Adam [26]
and Cybulsky et al [24]. Experiments were carried out in a 37°C
cabinet. Two peristaltic pumps were used to drive the perfusion
circuit (Extech equipment, Masterfiex), which included tubing
(0.187 inch ID x 0.313 inch OD) connecting a glass perfusate
reservoir, a glass film-oxygenator, an 8 m Millipore filter, a
flowmeter and a side arm pressure gauge. All glassware was
siliconized and the perfusate was gassed with 95% 02/5% CO2
mix.
Three days prior to perfusion, male Sprague-Dawly rats,
weighing 300 to 340 g were injected intravenously with 6 mg of
y2 sheep anti-rat Fx1A [24]. On the day of perfusions rats were
anaesthetized with an intraperitoneal injection of pentobarbi-
tone sodium (Boehringer Ingelheim, Australia; 0.12 mIJlOO g).
After an intravenous injection of 500 mg/kg mannitol, the right
ureter was cannulated with a PE1O catheter. The renal artery
was then cannulated with a glass cannula via the superior
mesenteric artery without interrupting blood flow. Perfusion
with BSA perfusate was commenced, the cannula tied in place
and the kidney and ureter dissected out and mounted in the
37°C cabinet.
The kidney was initially perfused with the BSA perfusate for
an equilibration period of approximately ten minutes. After this
period the perfusate was changed to the appropriate plasma
preparation. This was achieved by removal of the reservoir
return tube and flushing of the circuit with plasma perfusate for
a period of approximately five minutes. The kidney continued
to be perfused during this time. After this time the return tube
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was replaced and the reservoir filled with plasma. After 10
minutes perfusion with the plasma, 4 ml of heat-inactivated
guinea pig anti-sheep IgG, as whole antiserum containing
2 mg/mi of IgG, was then added to the perfusate to initiate
glomerular injury and measurements made.
During the two hour perfusion, perfusion pressure was ad-
justed to, and maintained at 95 to 99 mm Hg.
The perfusions were continued for a period of two hours,
during which samples of perfusate and urine were collected
every twenty minutes.
Adequacy of perfusions. Technically adequate perfusions
were defined as having a glomerular filtration rate (GFR) greater
than 0.4 mI/mm, a urine flow rate (UFR) comparable between
the two kidneys of each pair, a renal vascular resistance (RVR)
of less than 5 mm Hg• minlml and sodium reabsorption (FRNa)
greater than 75%.
Experimental design
All experiments were paired using separate perfusion cir-
cuits. In this way plasma from the same donor, collected and
depleted the previous day, was used in experimental (clusterin
depleted serum) and control (fibronectin depleted serum) per-
fusion at the same time.
Measurements
Glomerular filtration rate (GFR) was estimated by measure-
ment of inulin clearance using [3H] methoxy-inulmn (Amersham,
England, UK). Protein concentration in the urine samples were
determined by the Lowry assay [27] and expressed as protein
excretion rate (mg/mm). Sodium in urine and perfusate samples
was measured by a flame photometer. Perfusate flow rate was
recorded throughout and renal vascular resistance (RVR) was
calculated from the flow rate and perfusion pressure. Fractional
sodium reabsorption (FRNa%) was calculated from standard
formulas. Urine flow rate (UFR) was calculated from the
volume of urine excreted during each twenty-minute time
interval (mi/mm).
Production of antibodies
Monoclonal antibodies G7 and PHMJ3, G7 and PHMI3,
used to deplete plasma of clusterin and fibronectin, respec-
tively, have previously been characterized [1, 25]. Both of the
monoclonal antibodies are of the IgG I , isotype and were
prepared for coupling to the affinity matrix by ammonium
sulphate precipitation of ascites fluid, dialysis against 0.1 M
NaHCO3, 0.5 M NaC1 and adjusted to a protein concentration of
8 mg/ml with the same buffer.
y2 Sheep anti-rat FxJA. A sheep was immunized by repeated
monthly injections of rat FxlA, prepared as previously de-
scribed [28]. After collection of sheep antiserum, the y2 IgG
non-complement fixing subclass was isolated by ion-exchange
chromatography, heat-inactivated (56°C, 30 mm) and concen-
trated as described [28]. All of the antibody was pooled,
aliquoted and frozen at —70°C until use. In pilot experiments a
maximal subnephritogenic dose was determined to be 6 mg per
300 g rat.
Guinea pig anti-sheep IgG, whole anti-serum. Hartly guinea
pigs (Monash University Animal Services Center) were immu-
nized by repeated four monthly subcutaneous injections with
1 mg purified sheep IgG (Silenus, Melbourne, Australia) in
incomplete Freund's adjuvant (Sigma, Melbourne, Australia).
Serum was collected three weeks after the last immunization,
pooled, aliquoted and stored at —70°C until use. Prior to use,
serum was heat-inactivated for one hour at 56°C.
Affinity isolated guinea pig anti-sheep antibody was also
produced for radiolabeling in glomerular binding experiments.
Normal sheep IgG (Silenus) was coupled to cyanogen bromide
Sepharose-4B (Pharmacia, Sweden) as per manufacturer's in-
structions (7 to 10 mg IgG coupled to 10 ml matrix). The whole
guinea pig antiserum was passaged through the column and
bound antibody eluted with 1.75 M KSCN [24].
Complement assays
Total hemolytic complement activity of human plasma sam-
ples pre- and post-depletion was measured using Quantiplate,
Total Complement Test Kit (Kallestad Laboratories Inc., Aus-
tin, Texas, USA).
Concentrations of the third and fourth components of com-
plement (C3 and C4) were measured in plasma samples using a
Nephelometer (Behring) by the Clinical Immunology Labora-
tory, St. Vincent's Hospital.
Glomerular antibody binding
Glomerular binding of y2 sheep anti-FxIA to glomeruli.
Sheep anti-Fx1A, y2 fraction, 20 mg was iodinated with 4 mCi
of 1125 (Amersham) by the lacto-peroxidase technique [29]. This
was diluted with 20 mg cold antibody and 6 mg per rat injected
into six 300 to 340 g Sprague-Dawly rats. Specific activity was
0.1 Ci/jxg (2.2 x iO cpm/sg of protein).
Antibody binding was determined as described [30]. Three
days after injection of labeled antibody the rats were sacrificed.
Glomeruli were isolated by differential sieving [30], counted by
phase contrast microscopy and 1125 activity counted in a gamma
counter (Packard, AutoGamma 5110). Glomerular antibody
binding was expressed as micrograms per 38,000 glomeruli (the
average number of glomeruli per rat kidney [31]).
To control for non-specific binding of serum proteins, an
additional four rats were injected each with 6 mg 1251 labeled
BSA (2.0 x 1O cpm/g of protein). Three days later, glomeruli
were isolated and counted as in the 125J sheep anti-Fxla
experiments above.
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Fig. 1. Protein excretion in kidneys perfused with complement inactive
plasma. Protein excretion was low and no significant difference was
seen between clusterin (0; N = 2) or fibronectin (; N = 2) depleted
plasma.
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Table 2. Percentage concentration of fibronectin and clusterin remaining in plasma after depletion
Percentage remaining
(after affinity depletion) Total hemolytic
of original plasma concentrations complement
of clusterin/fibronectin C3 C4 U/mi
Normal plasma — 0.83—1.77 0.11—0.45 > 35
Clusterin depleted plasma 25.9 1.9% 0.26 0.02 0.04 0.003 26 3
Fibronectin depleted plasma 23.0 2.3% 0,27 0.02 0.04 0.002 26 5
Comparison of percentage remaining after depletion of clusterin and fibronectin and comparison between the groups of concentrations C3c,
C4(glliter) and total hemolytic complement activity (hemolytic units) are from the eight group 2 perfusions.
No significant difference was seen between the two groups of depleted plasma.
Time, minutes
Fig. 2. Eight pairs of kidneys perfused with fresh clusterin (El N = 8)
and fibronectin (• ; N = 8) depleted plasma. Mean protein excretion
rate with standard error over time of perfusion. Abnormal proteinuria
develops in both groups of perfused kidneys and is a significantly
greater when the kidneys are perfused with the plasma depleted of
clusterin.
Glomerular binding of guinea pig anti-sheep IgG. Guinea pig
anti-sheep IgG (5 mg) was affinity purified as described above
and iodinated with 1 mCi V25 (Amersham) by the lacto-perox-
idase technique [291. Three pairs of perfusions were performed
using the iodinated antibody, 2 mg of which was diluted into
aliquots of 4 ml of cold guinea pig anti-sheep IgG antiserum.
The specific activity was 0.1 pCi/ag (2.2 x l0 cpm/g of of
protein). Glomerular antibody binding was calculated and ex-
pressed as the number of glomeruli per rat kidney.
Histology, immunohistology, and electron microscopy
Immediately after completion of each perfusion, kidneys
were sectioned and portions taken for conventional histology,
immunohistochemistry and electron microscopy.
Immunofluorescence. For immunofluorescence, kidney tis-
sue was immersed in OCT compound (Miles, USA) and snap
frozen in dry ice-isopentane. Four micrometer frozen sections
were cut and fixed in acetone for ten minutes. Direct immuno-
fluorescence was performed with the following fluorescem
isothiocyanate conjugated (FITC) antisera: donkey anti-sheep
IgG, sheep anti-guinea pig IgG and sheep anti-human C3 (all
from Silenus).
Immunohistochemistry (APAAP technique). Kidney tissue
was fixed four hours in paraformaldehyde-lysine-periodate
(PLP) and equilibrated for 72 hours in 7% sucrose buffer before
being frozen in OCT compound (Miles) and dry ice-isopentane
[32]. The alkaline phosphatase anti-alkaline phosphatase
(APAAP) technique was used with monoclonal antibodies for
the detection of human complement components C8 (produced
in our laboratory), C9 [33], clusterin [1], vitronectin [22],
C5b-9/C9 neoantigen (Quidel, San Diego, California, USA), and
fibronectin [25].
Frozen sections of 4 m, PLP fixed tissue were fixed in
acetone for ten minutes. Incubation with mAb was followed by
successive incubations with a bridging antibody, rabbit anti-
mouse immuoglobulins (DAKO Z456) and the APAAP complex
(DAKO D651). The reaction product was developed with
substrate (Bio-Genics HK182-5K) and sections were counter-
stained with Harris hematoxylin and mounted with Permanent
Aqueous Mounting Medium (Bio/Can Scientific).
Scoring of immunohistology. Immunohistology and immuno-
fluorescence were scored semiquantitatively (0, 1+, 2+, 3+,
4+) by the same observer who was unaware of the experimental
group of the sections. Group results were then expressed as a
median score.
Light microscopy. For light microscopy, portions of kidney
were fixed in formol sublimate solution, dehydrated in graded
alcohols, cleared with chloroform and infiltrated with paraffin.
Two micron serial sections were cut and stained with hematox-
ylin and eosin [34].
Electron microscopy. For electron microscopy, sections
were fixed for three hours in 2.5% glutaraldehyde in 0.1 M
phosphate buffer pH 7.4, post-fixed in 0.1 M phosphate buffer
followed by 2% osmium tetroxide, and embedded in araldyte!
epon. Sections (68 nm) were cut using the Ultra cut E (Reichert-
Jung) and stained with 0.23 M uranyl acetate in 50/50 methanol!
ddH2) and Reynolds lead citrate. A Philips CM 10 electron
microscope was then used to examine the sections.
Statistics
Repeated measures analysis of variance was performed using
the SuperAnova package (Abbacus Concepts Berkely, Califor-
nia, USA) statistical package to determine the significance of
differences in protein excretion, GFR, RVR, and Na reabsorp-
tion between the two experimental groups. Repeated measures
analysis of covariance, using the SysStat package version 5.2,
was also performed in the clusterin depleted group to determine
whether the degree of proteinuria was related to the degree of
clusterin depletion.
Results
Three series of technically successful perfusions were per-
formed.
The results of the perfusions are described in three separate
groups: (1.) complement inactivated plasma; (2.) complement
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Table 3. Isolated perfused kidney function
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Period Time
1
0—20
2
20—40
3
40—60
4
60—80
5
80—100
6
100—120
Clusterin-depleted plasma group
RVR 3.2 0.2 3.8 0.3 4.2 0.3 4.6 0.4 4.8 0.4 5 0.4
GFR 0.6 0.1 0.68 0.1 0.54 0.1 0.56 0.1 0.6 0.1 0.5 0.1
FRNa 88 1.2 83 2.9 66 6.4 66 3.8 65 4.1 59 4.7
UFR 0.11 0.02 0.16 0.02 0.2 0.02 0.23 0.01 0.23 0.02 0.23 0.01
Fibronectin-depleted plasma group
RVR 3.2 0.2 3.3 0.2 3.5 0.2 3.7 0.2 4 0.2 4.1 0.2
GFR 0.89 0.1 0.66 0.1 0.7 0.1 0.56 0.1 0.54 0.1 0.55 0.1
FRNa 87 2.3 83 3 80 3.5 74 2.1 73 2.9 70 6.3
UFR 0.15 0.02 0.15 0.02 0.19 0.04 0.2 0.04 0.19 0.03 0.17 0.02
All values are expressed as mean SE. Abbreviations are: RVR, renal vascular resistance (mm Hg . minim)); GFR, glomerular filtration rate
(mI/mm); FRNa, sodium reabsorption (%); UFR, urine flow rate (mI/mm). The function of the eight paired isolated kidney perfusions (group 2) are
reflected in the GFR, RVR, FRNa and UFR. For each of these variables a repeated measures analysis of variance was performed to determine
whether there was any effect of group (clusterin depleted or fibronectin depleted). There was no significant effect (at the 0.05 level) of group on
any of the functional parameters.
Time, minutes
Fig. 3. Three pairs of fresh plasma perfusions with "inadequate"
clusterin depletion. Mean protein excretion with standard error over the
time of perfusion. There is no significant difference in proteinuria
between kidneys perfused with fibronectin depleted plasma (S; N = 3)
and those perfused with plasma inadequately depleted of clusterin (0;
N 3).
active and adequately depleted plasma; and (3.) complement
active plasma with inadequate clusterin depletion.
Adequacy of clusterin and fibronectin depletion and
complement inactivation of some plasma samples
Depletion of plasma clusterin or fibronectin to 30% of the
initial concentration was readily achievable with the affinity
chromatography, and this level of depletion was arbitrarily
selected to define adequate depletion for the experimental and
control groups. Determination of the degree of depletion was
performed after each perfusion; hence a series of three perfu-
sions were performed with inadequate clusterin depletion due
to a failure of the affinity column.
Determination of the complement activity of depleted plasma
was also performed after completion of the perfusion, and two
perfusions were performed with plasma which was subse-
quently found to be complement inactivated. The results of
these perfusions do, however, serve as additional controls and
are described as groups 1 and 3 below.
0
150
Time, minutes
Fig. 4. Relationship between degree clusterin depletion and protein-
uria. Symbols are: (El) 16%; (D) 19%; (El) 26%; ('0') 28%; (A) 30%; (•)
30%; (U) 30%; (A) 28%. Individual plasma samples from perfusions
were tested for clusterin depletion by ELISA and these data plotted
against proteinuria over time for the individual perfusions.
Group 1. Perfusions with complement inactivated plasma. It
was initially intended to perform perfusions with heat-inacti-
vated plasma (56°C, 45 mm) to confirm complement depen-
dance of this model. Heat-inactivation, however, resulted in
protein aggregation which rendered the plasma non-filterable. A
serendipitous complement inactive control group was identified
in the series of two initial pairs of perfusions which were
performed using plasma which had been passaged through the
affinity columns without prior addition of EDTA. This resulted
in significant complement activation on the affinity column and
reduction in subsequent total hemolytic complement activity in
both clusterin and fibronectin depleted plasma (<5%). On
perfusion of kidneys with these plasma preparations, no in-
crease in proteinuria occurred, as shown in Figure 1. The
excreted protein levels remained low throughout the perfusion
and there was no significant difference between clustenn and
fibronectin depleted plasma.
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Fig. 5. Direct immunofluorescence on
sections of perfused kidneys. (a), (C) and (e).
Kidneys perfused with clusterin depleted
plasma with detection of sheep IgG, guinea
pig IgG and human C3c, respectively. (b), (d)
and (f). Kidneys perfused with fibronectin
depleted plasma with detection of sheep IgO,
guinea pig IgG and human C3c, respectively.
There are no differences between the groups.
Group 2. Clusterin-depleted complement active perfusions.
Eight successful pairs of perfusions were performed using fresh
human plasma that had been depleted the previous day, with all
clusterin and fibronectin depletion to less than 30% of initial
concentrations (range 30 to 15%). The total hemolytic comple-
ment activity, C3 and C4 levels for both groups are shown in
Table 2. In both groups there was a significant increase in
urinary protein excretion over the time of the perfusion. The
kidneys perfused with clusterin depleted plasma, however,
showed a significantly greater increase in proteinuria as com-
pared to the fibronectin depleted control (Fig. 2). Analysis of
variance showed a significant difference (P < 0.01) in the
protein excretion between the groups. There was no significant
difference, using repeated measures analysis of variance, be-
tween the groups with respect to GFR, RVR, Na reabsorption
and UFR (Table 3).
Group 3. Inadequate clusterin depleted-complement active
perfusions. Three successive paired perfusions were, retrospec-
tively, found to have insufficient depletion of clusterin (80 to
70% of initial concentration) due to a failure of the G7 affinity
column. Fibronectin depletion was adequate in these perfusions
(depletion to 30%) and there was no difference in the total
hemolytic complement activity, C3 and C4 levels between the
groups. Proteinuria in these pairs, showed no significant differ-
ence between the clusterin and fibronectin depleted plasma
perfusions (Fig. 3). The protein excretion in all perfusions in
group 3 was comparable to that seen in the fibronectin-depleted
plasma perfusions in group 2. These data suggest that "ade-
quate clusterin depletion" was responsible for the enhanced
proteinuria in group 2.
Correlation between the degree of clusterin depletion and
proteinuria
To further analyze the effect of the degree of clusterin
depletion on the resultant proteinuria, the data from group 2
were analyzed in relation to the degree of clusterin depletion.
As can be seen in Figure 4, there was a relationship between the
protein excretion rate in kidneys perfused with clusterin de-
pleted plasma and the extent of the clusterin depletion. Using
repeated measures analysis of covariance on the data in Figure
4, the percentage clusterin depletion was shown to have a
significant independant effect on proteinuria (P < 0.01).
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Table 4. Fluorescence and APAAP labeling of tissue sections of perfused kidneys and glomerular binding of guinea pig anti-sheep IgG
Clusterin-depleted plasma
perfused kidneys
Fibronectin-depleted plasma
perfused kidneys
Kidneys perfused with
complement inactivated
plasma
Fluorescence
ShlgG ++++ ++++ ++++
GPIgG ++++ ++++ ++++
Human C3c + + + + + + trace
APAAP
C8 ++ + —
C9 -I-++ + —
C5b-9neo. +++ + —
clusterin — — —
vitronectin trace trace trace
fibronectin + + +
Glomerular binding of guinea 3.1 0.9 2.8 1.1 not done
pig anti-sheep IgG
g/38,000 glomeruli, mean
SEM
Histology, immunohistology and electron microscopy
Histological examination of kidneys from both the clusterin
depleted and fibronectin depleted groups showed no significant
abnormalities by light microscopy.
Immunofluorescence. All kidneys showed a granular deposi-
tion of sheep IgG (Fig. 5 a, b) and guinea pig IgG (Fig. 5 c, d).
Human C3 (Fig. 5 e, 1) was detected along the glomerular
capillary walls in the kidneys from group 2, but only trace
amounts were found in group I kidneys perfused with comple-
ment inactive plasma. In group 2, there was no detectable
difference in fluorescence intensity between kidneys perfused
with clusterin depleted plasma and those perfused with fi-
bronectin depleted plasma (Fig. 5, Table 4).
Immunohistochemistry (APAAP). Deposition of the terminal
complement components C8 and C9, along with the CSb-9
neoantigen (Fig. 6 a, b, c) were seen to be greater in the
glomeruli of kidneys perfused with plasma depleted of clusterin
(Table 4).
Clusterin deposition was seen in the vessels in both groups of
kidneys, but there was no detectable glomerular clusterin in
either group. Fibronectin was detected at low levels in the
mesangium of glomeruli with no difference between kidney
groups and vitronectin showed trace deposition (0.5+) in the
glomeruli with no significant difference between the groups
(Table 4).
Electron microscopy. Electron microscopy showed a differ-
ence between the two groups of perfused kidneys. Kidneys
perfused with clusterin depleted plasma showed greater efface-
ment and detachment of the podocyte foot processes compared
to the kidneys perfused with the fibronectin depleted plasma
(Fig. 7 A, B). Kidneys from both groups showed small subep-
ithelial electron dense deposits (Fig. 7 arrows).
Glomerular antibody binding
Glomerular binding of y2 sheep anti-FxJA. Mean glomeruli
antibody binding of the y2 sheep anti-Fx1A in the five rats
studied was 17 2.3 p.g/38,000 glomeruli. In the four control
rats injected with 1251 BSA there was no detectable binding of
BSA (<1 g/38,00O glomeruli).
Glomerular binding of guinea pig anti-sheep IgG. Glomerular
binding of guinea pig anti-sheep IgG, following perfusion with
clusterin depleted plasma was 3.1 0.9 g/38,00O glomeruli,
compared to a binding of 2.8 1.1 xg/38,00O following perfu-
sion with fibronectin depleted plasma. This difference was not
significant.
Discussion
The initial perfusions in this study using complement inactive
plasma confirmed previous findings that this model of PHN in
the IPK is complement dependant [24].
In the main experiments (group 2) there was significantly
greater proteinuria when perfusions were with plasma depleted
of plasma clusterin to less than 30% of initial concentration.
These data, together with the fact that the degree of clusterin
depletion was related to the level of proteinuria, suggests that
clustenn depletion enhanced glomerular injury in this model.
The binding studies and immunohistology showed similar
binding of sheep and guinea pig IgG and of C3 in both clusterin
and fibronectin depleted plasma perfused kidneys, despite the
differences in protein excretion. Accordingly, it is unlikely that
clusterin depletion affected the initiation of immune glomerular
injury or the activation of early complement pathways. How-
ever, deposition of glomerular C5b-9/C9 neoantigen along with
the individual terminal components C8 and C9 was significantly
different between the two groups. Kidneys perfused with
plasma depleted of clusterin showed greater deposition of C5b-9
components. This supports the hypothesis that the increase in
proteinuria seen following depletion of clusterin is due to
greater damage to the glomerular epithelial cells by C5b-9.
No glomerular clusterin deposition and only trace amounts of
vitronectin were seen in any of the perfused kidneys. Clusterin
and vitronectin are detected at day 5 in in vivo models of PHN
[21], but it is unclear why the soluble SC5b-9 complex is an
apparently stable component of glomeruli in the later stages of
experimental glomerulonephritis and in human glomerulone-
phritis [18]. The absence of clusterin or significant amounts of
vitronectin in the glomeruli of either of our IPK groups, despite
significant C5b-9 deposition, suggests that all the C5b-9 is in the
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Fig. 6. AFAAP on FLP fixed perfused kidney
sections. Neoantigen CSb-9/C9 was deposited
in greater amounts in the glomeruli of kidneys
perfused with clusterin depleted plasma (a)
when compared with fibroneetin-depleted
perfused kidneys (b). Kidneys perfused with
complement inactive plasma contained no
glomerular CSb-9 (c). Reproduction of this
figure in color was made possible by a grant
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Fig. 7. Electron microscopy shows marked effacement of epithelial ceilfoot processes in the clusterin-depleted plasma perfused kidneys (A), with
lesser abnormality in the fibronectin-depleted plasma perfused kidneys (B). Subepithelial deposits are seen in both groups of kidneys (arrows).
phospholipid membrane bound C5b-9(m) form. The failure to
detect SC5b-9 complexes in the glomeruli could indicate that
SC5b-9 complexes accumulate at a slow rate in this system and
were therefore not detectable after only a two hour perfusion.
Alternatively SC5b-9 complexes may have formed but did not
remain in the glomeruli after perfusion and/or tissue processing.
Despite the absence of glomerular clusterin/SC5b-9 in either
group, clusterin depletion of the perfused plasma was associ-
ated with significantly greater glomerular C5b-9(m) deposition.
This suggests that clusterin may normally have an inhibitory
effect on the assembly of C5b-9(m) on cell membranes or that
some of the complement activation in this model occurs adja-
cent to the cell membrane, leading to "bystander" lysis.
Bystander lysis is typically inhibited by fluid phase regulators of
C5b-9 such as clusterin.
The ultrastructural studies confirm that greater abnormality
of the podocytes was seen in the clusterin depleted plasma
perfused kidney. These data accord with those of Cybuisky et al
[24] who showed a relationship between proteinuria and
podocyte damage.
It is possible that depletion of plasma fibronectin in our
control group may have, in some way, decreased glomerular
injury. This seems unlikely to be responsible for the differences
observed as the proteinuria seen in the control (fibronectin
depleted) group was similar to that seen when plasma was
passaged through a column of uncoupled sepharose CnBr 4B
(4 mg/mm at 120 mm) and was similar to the proteinuria
observed by Cybuisky et al [24] in perfusions with 55% diluted
human plasma. Furthermore the similarity in proteinuria be-
tween groups when clusterin depletion was "inadequate"
(group 3) suggests that it was the clusterin depletion itself that
was principally responsible for the difference in proteinuria.
There are a number of inhibitors of the C5b-9 that could
potentially limit glomerular injury in this system. For example,
rat podocytes presumably express the rat homolog of the
GPI-linked membrane complement inhibitor CD59 [35, 36].
This molecule, at least in the human, functions principally as an
inhibitor of lysis by homologous complement along with the
other membrane inhibitors of the earlier complement pathways,
for example decay accelerating factor [37, 38]. In this IPK
system, with heterologous plasma perfusion, it is probable that
the cell membrane related inhibitory proteins in the rat kidney
would be less efficient inhibitors of complement activation.
Indeed, it is very likely that, even in the absence of antibody
administration, perfusion of rat kidneys with human plasma
would result in significant complement activation as a result of
naturally occurring xenoantibody and loss of homologous re-
striction. In this context, it is possible that the human soluble
plasma inhibitors of the assembly of C5b-9, clusterin and
vitronectin, may play a relatively more significant role in
regulation of complement activation. As a result, a 30% deple-
tion of clusterin is able to produce a substantial enhancement of
complement mediated injury.
Whether or not the significance of clusterin as a C5b-9
inhibitor is artificially enhanced in this model, it is now clear
from these data that clusterin is able to inhibit complement in
vivo. This is the first demonstration of a likely functional
complement inhibition by clusterin outside of an in vitro lysis
system.
It is clear from recent work from many groups, that clustenn
has numerous likely biological functions outside of the comple-
ment system [39, 40]. It binds to lipid and some lipoproteins, it
is present in secretory vesicles of the adrenal medulla and
canine kidney epithelial cells, it is constitutively expressed at
high levels in the reproductive tracts and probably the brains of
all mammals and is present in most human bodily secretions.
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Taken together with the known increase in clusterin expression
following cell injury, the suggestion has been made [41] that
clusterin functions as a form of "membrane policeman" in-
volved not only in the protection of membranes from comple-
ment, but also involved in membrane associated secretion,
removal or remodeling of membranes during injury or develop-
ment. It may therefore be that in these studies, the apparent
partial protection from injury afforded by normal plasma clus-
term concentrations was not wholly specific for complement-
mediated cell injury. The role of clusterin in the control of
non-complement-dependant glomerular cell injury is worthy of
study in the future.
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